NVO - looking for move upMy MVP system
M: rsi bottoming, rounded w a higher low
V: solid increase in vol
P: steep downward channel; could have nice pop to the upside; I would like the price better if it were forming a base instead of a steep down path, though price did hit a prior support/resistance zone
*Im wondering if
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
3.15 EUR
13.50 B EUR
38.82 B EUR
3.16 B
About NOVO NORDISK B A/S
Sector
Industry
CEO
Lars Fruergaard Jørgensen
Website
Headquarters
Bagsværd
Founded
1931
ISIN
DK0062498333
FIGI
BBG000DYN870
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
NOV - CONTINUATION OF A DOWNTREND OR START OF A NEWGood Morning,
Hope all is well. NVO has been in a down trend since Feb 26 2025, like most stocks. NVO tried to move past the 70$ price point however it was rejected and is now seeking lower support. Currently for trend there is an ascending channel. A break above the mid-line is bullish, a failure
NVO buyThis downturn has been influenced by several factors:
Leadership Changes: CEO Lars Fruergaard Jørgensen is stepping down after eight years, following a sharp decline in the company's stock price.
STAT
+8
MarketWatch
+8
WSJ
+8
Increased Competition: Eli Lilly's weight-loss drugs, Mounjaro and Zepb
Novo Nordisk Stock Chart Fibonacci Analysis 050925Trading Idea
1) Find a FIBO slingshot
2) Check FIBO 61.80% level
3) Entry Point > 411/61.80%
Chart time frame: D
A) 15 min(1W-3M)
B) 1 hr(3M-6M)
C) 4 hr(6M-1year)
D) 1 day(1-3years)
Stock progress: A
A) Keep rising over 61.80% resistance
B) 61.80% resistance
C) 61.80% support
D) Hit the bottom
Novo Nordisk (NVO) – Oversold Reversal + Earnings CatalystNovo Nordisk (NVO) has declined 61.13% from its all-time high of $148 (June 2024), finding support at $57.55. Over the past two weeks, the stock has rebounded over 15%, currently trading around $66.30, with strong reversal signals just ahead of earnings.
This setup presents a compelling opportunity
NVO Thesis earningsEarnings from LLY proved to be good on their fat drugs with concerns on tariffs for other items in their portfolio. Knowing that NVO is primary obesity with deals on the table from CVS and HIMS it is in the line of thinking that earnings will be in line with positive guidance in anticipation of mar
NVO Novo Nordisk: $195 | The Cure since forever it addresses on major conditions of humans
Diabetes Cardio Alzheimer's
from acquisition to partnering and continuous r&d
this issue is a model to new science and tech companies making it to the next 50 years
key is innovation
opportunity is wait for major crash to upsize for OG investors
or s
Novo Nordisk's The recent drop in Novo Nordisk's stock price is attributed to several factors. A key issue is the company’s struggle to meet the surging demand for its weight-loss drugs, such as Wegovy. Although demand remains strong, investors are concerned about Novo Nordisk's ability to scale up production and
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where NOV is featured.
Related stocks
Frequently Asked Questions
The current price of NOV is 57.57 EUR — it has decreased by −3.06% in the past 24 hours. Watch NOVO-NORDISK AS B DK 0,1 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange NOVO-NORDISK AS B DK 0,1 stocks are traded under the ticker NOV.
NOV stock has fallen by −1.05% compared to the previous week, the month change is a 1.20% rise, over the last year NOVO-NORDISK AS B DK 0,1 has showed a −53.20% decrease.
We've gathered analysts' opinions on NOVO-NORDISK AS B DK 0,1 future price: according to them, NOV price has a max estimate of 120.35 EUR and a min estimate of 46.80 EUR. Watch NOV chart and read a more detailed NOVO-NORDISK AS B DK 0,1 stock forecast: see what analysts think of NOVO-NORDISK AS B DK 0,1 and suggest that you do with its stocks.
NOV stock is 8.35% volatile and has beta coefficient of 1.40. Track NOVO-NORDISK AS B DK 0,1 stock price on the chart and check out the list of the most volatile stocks — is NOVO-NORDISK AS B DK 0,1 there?
Today NOVO-NORDISK AS B DK 0,1 has the market capitalization of 253.31 B, it has decreased by −1.81% over the last week.
Yes, you can track NOVO-NORDISK AS B DK 0,1 financials in yearly and quarterly reports right on TradingView.
NOVO-NORDISK AS B DK 0,1 is going to release the next earnings report on Aug 6, 2025. Keep track of upcoming events with our Earnings Calendar.
NOV earnings for the last quarter are 0.87 EUR per share, whereas the estimation was 0.82 EUR resulting in a 6.95% surprise. The estimated earnings for the next quarter are 0.80 EUR per share. See more details about NOVO-NORDISK AS B DK 0,1 earnings.
NOVO-NORDISK AS B DK 0,1 revenue for the last quarter amounts to 10.46 B EUR, despite the estimated figure of 10.44 B EUR. In the next quarter, revenue is expected to reach 10.44 B EUR.
NOV net income for the last quarter is 3.89 B EUR, while the quarter before that showed 3.77 B EUR of net income which accounts for 3.03% change. Track more NOVO-NORDISK AS B DK 0,1 financial stats to get the full picture.
NOVO-NORDISK AS B DK 0,1 dividend yield was 1.83% in 2024, and payout ratio reached 50.28%. The year before the numbers were 1.35% and 50.35% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of May 19, 2025, the company has 76.3 K employees. See our rating of the largest employees — is NOVO-NORDISK AS B DK 0,1 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVO-NORDISK AS B DK 0,1 EBITDA is 21.00 B EUR, and current EBITDA margin is 50.95%. See more stats in NOVO-NORDISK AS B DK 0,1 financial statements.
Like other stocks, NOV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVO-NORDISK AS B DK 0,1 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVO-NORDISK AS B DK 0,1 technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVO-NORDISK AS B DK 0,1 stock shows the sell signal. See more of NOVO-NORDISK AS B DK 0,1 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.